Healthcare consultant, summited Kilimanjaro on team Timmerman @climbtofight, Fellow @AspenInstitute
Manhattan, NY
Joined July 2009
- Tweets89
- Following345
- Followers191
- Likes244
Kirsten Axelsen (she/her) retweeted
Kirsten Axelsen @DLA_Piper breaks down the debate over whether Medicare drug price negotiations could discourage pharmaceutical companies from investing in new uses for existing medicines. healthaffairs.org/content/fo…
Kirsten Axelsen (she/her) retweeted
As some #IRA provisions take effect for the first time in 2025, a DLA Piper assessment of how the number and types of #Medicare plans changed over the last three years poses potential considerations for policy makers: spr.ly/6010xi4y2
#LifeSciences #Insurance #Healthcare
ALT Life Sciences alert
Kirsten Axelsen (she/her) retweeted
Join Incubate and @DLA_Piper during #JPM2025 for a #biopharma and #healthpolicy panel featuring @nkjellson, @kjacny, @johnbstanford, and Gaurav Gupta. RSVP here: eventbrite.com/e/the-outlook…
Coverage of Obesity Medications Can Make America Healthier (Again) realclearhealth.com/blog/202…
The IRA And Post-Approval Clinical Research For Cancer Medicines aei.org/articles/the-ira-and…
Kirsten Axelsen (she/her) retweeted
There is a pressing need for robust evidence to inform biopharmaceutical policy, @kjacny and co-authors write in Health Affairs Scholar.
The article is part of a new series that explores financial rewards for new drugs and R&D investment. @ITIFdc
bit.ly/48gciw8
If we import other countries' drug policy we also import their outcomes ...
biospace.com/policy/opinion-…
Kirsten Axelsen (she/her) retweeted
Excited to read this analysis of the IRA’s potential impact on cancer drug R&D — including the detailed, transparent methods! crai.com/insights-events/pub…
Price controls on medicines save money for the federal government, but not necessarily for consumers washex.am/3bh1zIr
Join me on 5/23 for a @KFF virtual conversation on what the Biden Administration could do to address drug affordability.
With other experts, we’ll explore the drivers of rising prescription drug prices and potential administrative actions to address them. us02web.zoom.us/webinar/regi…
Future of Healthcare Summit: Tackling Costs thehill.com/event/579612-fut…
New Research Proposes Metrics, Measures, and Models Promoting Health Equity via @ptechealth and @academyhealth shar.es/aWZwgp
Kirsten Axelsen (she/her) retweeted
The #ACA expanded insurance coverage requirements for preventive care services and included other provisions intended to increase their use. However, in a new @AEI report, @kjacny, @KieranAllsop, and Sara Rogers show the use of these services has declined: aei.org/research-products/re…
Who needs the Oscars when you have @AEI recommending film and television aei.org/economics/aeis-film-…
Join us for @bhangrajay and Christina Floyd on Feb 22nd noon EST ptechealth.org/events focus on data collection and information for greater equity in healthcare delivery
Kirsten Axelsen (she/her) retweeted
Our first panel of the day will begin at 11:15 AM ET on "State Price Controls for #Pharmaceutical Products" featuring @kjacny (@AEI), @skaminerd (@P4ADNOW), @Maybarduk (@Public_Citizen) and Steven Horwitz (@ballstatebound)
![[LIVE WEBINAR] State Price Controls for Pharmaceutical Products](https://pbs.twimg.com/media/EsvVvzQW4AMB0dl.png?name=orig)
ALT [LIVE WEBINAR] State Price Controls for Pharmaceutical Products
Join today at noon EST ptechealth.org/events discussion of equity in health system design and administration